Observational studyJournal of gynecologic oncology2026
External validation of the SUCCOR Risk score for predicting recurrence in early-stage cervical cancer patients treated with radical hysterectomy.
Observational study in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo externally validate the Surgery in Cervical Cancer, Observational, Retrospective (SUCCOR) Risk score for predicting recurrence in early-stage cervical cancer treated with radical hysterectomy in a Thai population.
methodsA retrospective cohort of patients with the International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage IB1 cervical cancer who underwent radical hysterectomy at our institution between 2003 and 2019 was analyzed. The SUCCOR Risk score was calculated using original model specifications. Progression-free survival (PFS) and overall survival were estimated by Kaplan-Meier analysis and compared across risk groups. Model performance was evaluated in terms of discrimination, calibration, and overall accuracy.
resultsOf 1,309 eligible cases, 954 met the inclusion criteria. After a median follow-up of 79 months, 83 relapses (8.7%) and 66 deaths (6.9%) were observed. Five-year PFS was 95.3% in the low-risk, 88.0% in the medium-risk, and 88.0% in the high-risk groups (log-rank p=0.002). Medium-risk patients had a significantly higher relapse risk than low-risk patients (HR=2.62; 95% CI=1.51-4.53). The SUCCOR Risk score demonstrated moderate discrimination for 5-year relapse (area under the receiver operating characteristic curve=0.65; Harrell's c-statistic=0.68). Calibration analyses showed good average agreement but an attenuated calibration slope of 0.72, reflecting overdispersion of risk predictions. Overall model performance was useful, with a 5-year Brier score of 0.068 and an integrated Brier score (IBS) of 0.080, outperforming the null model (IBS=0.084).
conclusionThe SUCCOR Risk score maintained moderate discriminative ability and acceptable calibration in this Thai cohort, with modest improvement over baseline prediction. These findings support its generalizability across diverse clinical settings, though recalibration may enhance accuracy for local application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.